Tisagenlecleucel - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Tisagenlecleucel

Brand Name:

Kymriah

Strength:

consult labeling

HCPCS:

Not yet assigned

SEER*Rx Category:

Immunotherapy

Major Drug Class:

CAR-T

Minor Drug Class:

CD19

Oral (Y/N):

No

FDA Approval Year:

2017

FDA Discontinuation Year:

CMS Effective Date:

CMS Discontinuation Date:

Status:

In Use